Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

A role for bone turnover markers β-CrossLaps (CTX) and amino-terminal propeptide of type I collagen (PINP) as potential indicators for disease progression from MGUS to multiple myeloma.

Vallet S, Hoyle NR, Kyle RA, Podar K, Pecherstorfer M.

Leuk Lymphoma. 2018 Oct;59(10):2431-2438. doi: 10.1080/10428194.2017.1421757. Epub 2018 Jan 18.

PMID:
29345175
2.

Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability.

Szulc P, Naylor K, Hoyle NR, Eastell R, Leary ET; National Bone Health Alliance Bone Turnover Marker Project.

Osteoporos Int. 2017 Sep;28(9):2541-2556. doi: 10.1007/s00198-017-4082-4. Epub 2017 Jun 19. Review.

PMID:
28631236
3.

Biochemical bone turnover markers are useful tools to assess changes in bone metabolism in marmosets.

Angeliewa A, Budde M, Schlachter M, Hoyle NR, Bauss F.

J Bone Miner Metab. 2004;22(3):192-7.

PMID:
15108060
4.

Evaluation of plasma carboxy-terminal cross-linking telopeptide of type I collagen concentration in horses.

Carstanjen B, Hoyle NR, Gabriel A, Hars O, Sandersen C, Amory H, Remy B.

Am J Vet Res. 2004 Jan;65(1):104-9.

PMID:
14719711
5.

Effect of feeding on bone turnover markers and its impact on biological variability of measurements.

Clowes JA, Hannon RA, Yap TS, Hoyle NR, Blumsohn A, Eastell R.

Bone. 2002 Jun;30(6):886-90.

PMID:
12052458
6.

Myelin basic protein concentrations in the CSF of children receiving methotrexate.

Pinkerton CR, Chessells JM, Hoyle NR.

J Clin Oncol. 1986 Jan;4(1):112-3. No abstract available.

PMID:
2416887
7.

Cerebrospinal fluid myelin basic protein immunoreactivity as an indicator of brain damage in children.

Levin SD, Hoyle NR, Brown JK, Thomas DG.

Dev Med Child Neurol. 1985 Dec;27(6):807-13.

PMID:
2419189
8.

Neuropeptides in neurological tumours.

Allen JM, Hoyle NR, Yeats JC, Ghatei MA, Thomas DG, Bloom SR.

J Neurooncol. 1985;3(3):197-202.

PMID:
2414412
9.

Pre- and postoperative changes in serum myelin basic protein immunoreactivity in neurosurgical patients.

Hoyle NR, Seeldrayers PA, Moussa AH, Paul EA, Thomas DG.

J Neurosurg. 1984 Jul;61(1):49-52.

PMID:
6202857
10.

Effect of electroconvulsive therapy on serum myelin basic protein immunoreactivity.

Hoyle NR, Pratt RT, Thomas DG.

Br Med J (Clin Res Ed). 1984 Apr 14;288(6424):1110-1.

11.

Myelin basic protein immunoreactivity in serum of neurosurgical patients.

Thomas DG, Hoyle NR, Seeldrayers P.

J Neurol Neurosurg Psychiatry. 1984 Feb;47(2):173-5.

12.

Pre- and post-operative changes in serum immunoglobulin level in neurosurgical patients.

Seeldrayers PA, Hoyle NR, Thomas DG.

Acta Neurochir (Wien). 1984;70(3-4):269-74.

PMID:
6711368
13.

Serum MBP immunoreactivity and immunoglobulin level as markers of tumour type.

Seeldrayers PA, Hoyle NR, Thomas DG.

J Neurooncol. 1984;2(2):141-5.

PMID:
6207275
15.

Self and non-self in the brain.

Darling JL, Hoyle NR, Thomas DG.

Immunol Today. 1981 Sep;2(9):176-81. doi: 10.1016/0167-5699(81)90059-1. No abstract available.

PMID:
25290073

Supplemental Content

Loading ...
Support Center